However, CAR T cells from patients who responded to therapy exhibited superior expansion and produced higher levels of IL-2 after a 5-day exposure to CD19 expressing tumor cells compared to CAR T cells obtained from patients not responding to CAR T cells (Figure 4E). The gene discussed is CD19; the disease is neoplasm.